{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:36:06Z","timestamp":1793810166566,"version":"4.6.1"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Cambridge Biomedical Research Centre","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The management of inflammatory bowel disease (IBD) varies due to differences in healthcare systems, treatment costs, access to diagnostics, and diverse clinical practices between specialists. Despite the frequent advocacy of a treat-to-target (T2T) approach, there is insufficient clarity on how clinicians implement T2T in real-world settings. We aim to conduct a large, global survey among IBD experts to identify current practices in management. Methods: A prospective, cross-sectional study was conducted using a 16-item survey divided into two sections\u2014for ulcerative colitis (UC) and Crohn\u2019s disease (CD)\u2014and distributed to practicing IBD clinicians. Results: A total of 261 respondents from 88 countries participated in the survey, with the majority (253\/261) being physicians and eight being IBD nurse specialists. Despite global guidance, only a quarter of the respondents routinely perform an endoscopy to assess the response after starting an advanced therapy (28.4% in UC vs. 23.5% in CD). Moreover, despite an increasing academic focus on intestinal ultrasound (IUS), 171 (66%) of respondents in UC and 132 (51%) in CD reported that they do not routinely undertake IUS to guide treatment decisions. Faecal calprotectin for monitoring treatment response was routinely used by 87% (90% in UC and 84% in CD) of the respondents. Forty-five percent reported use of therapeutic drug monitoring (TDM) both proactively and reactively and 35% reported only using TDM reactively. Conclusions: Our study shows considerable variation in IBD management across different countries and interpretation of the T2T approach. This highlights the need for standardised and pragmatic guidelines to help improve outcomes for patients with IBD globally.<\/jats:p>","DOI":"10.3390\/jcm14030667","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:47:42Z","timestamp":1737438462000},"page":"667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International Survey"],"prefix":"10.3390","volume":"14","author":[{"given":"Mohmmed Tauseef","family":"Sharip","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Brezina","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"De La Revilla Negro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhar","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"},{"name":"Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3426-6408","authenticated-orcid":false,"given":"Nurulamin M.","family":"Noor","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"},{"name":"Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/apt.18294","article-title":"Review article: Novel therapies in inflammatory bowel disease\u2014An update for clinicians","volume":"60","author":"Noor","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: A population-based study","volume":"5","author":"Burisch","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","article-title":"Quality of Care Standards in Inflammatory Bowel Diseases: A European Crohn\u2019s and Colitis Organisation [ECCO] Position Paper","volume":"14","author":"Fiorino","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_4","first-page":"1583","article-title":"A Core Outcome Set for inflammatory bowel diseases: Development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process","volume":"18","author":"Fierens","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00535-023-02013-7","article-title":"Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis","volume":"58","author":"Parkes","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review","volume":"114","author":"Ungaro","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review","volume":"14","author":"Colombel","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"West, J., Tan, K., Devi, J., Macrae, F., Christensen, B., and Segal, J.P. (2023). Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196292"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_10","first-page":"4","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jgh.13923","article-title":"Limited uptake of ulcerative colitis \u201ctreat-to-target\u201d recommendations in real-world practice","volume":"33","author":"Bryant","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ueg2.12423","article-title":"Real-world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey","volume":"11","author":"Nardone","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000528070","article-title":"Significant Differences in IBD Care and Education across Europe: Results of the Pan-European VIPER Survey","volume":"41","author":"Kral","year":"2023","journal-title":"Dig. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1097\/MEG.0000000000002276","article-title":"Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): Results from an international survey","volume":"33","author":"Ding","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): A multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ueg2.12572","article-title":"Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study","volume":"12","author":"Bamias","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000487589","article-title":"Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn\u2019s Disease","volume":"36","author":"Laterza","year":"2018","journal-title":"Dig. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00535-023-01958-z","article-title":"Treatment escalation and de-escalation decisions in Crohn\u2019s disease: Delphi consensus recommendations from Japan, 2021","volume":"58","author":"Nakase","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/flgastro-2022-102309","article-title":"How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?","volume":"14","author":"Meade","year":"2023","journal-title":"Frontline Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): A multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"ref_21","first-page":"14309","article-title":"When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease","volume":"10","author":"Systrom","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/MIB.0000000000001140","article-title":"Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease","volume":"23","author":"Buisson","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ibd\/izac136","article-title":"Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019","volume":"29","author":"Yang","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/flgastro-2022-102157","article-title":"National census of UK endoscopy services 2021","volume":"13","author":"Ravindran","year":"2022","journal-title":"Frontline Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.3748\/wjg.v29.i15.2272","article-title":"Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making","volume":"29","author":"Dolinger","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ibd\/izad043","article-title":"Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study","volume":"30","author":"Goodsall","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00330-013-2973-0","article-title":"Ultrasound as a diagnostic tool in detecting active Crohn\u2019s disease: A meta-analysis of prospective studies","volume":"24","author":"Dong","year":"2014","journal-title":"Eur. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","article-title":"Evolving therapeutic goals in ulcerative colitis: Towards disease clearance","volume":"17","author":"Danese","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cgh.2013.07.022","article-title":"Histologic remission: The ultimate therapeutic goal in ulcerative colitis?","volume":"12","author":"Bressenot","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"i92","DOI":"10.1093\/ecco-jcc\/jjad212.0051","article-title":"DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial","volume":"18 (Supppl. S1)","author":"Jairath","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2019-318256","article-title":"Tight control for Crohn\u2019s disease with adalimumab-based treatment is cost-effective: An economic assessment of the CALM trial","volume":"69","author":"Panaccione","year":"2020","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"rkae030","DOI":"10.1093\/rap\/rkae030","article-title":"Overcoming provider barriers to therapeutic drug monitoring of tumour necrosis factor inhibitors for rheumatoid arthritis: A qualitative analysis","volume":"8","author":"Gavan","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): A multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"EVIDoa2200061","DOI":"10.1056\/EVIDoa2200061","article-title":"Discontinuation of Infliximab Therapy in Patients with Crohn\u2019s Disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): A multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:32:41Z","timestamp":1759919561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030667"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030667","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]}}}